VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Inclacumab was generally well tolerated in THRIVE-131
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The submission is supported by results from the Phase 3b APEX study
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Subscribe To Our Newsletter & Stay Updated
